CD47 and acute myeloid leukemia: In preclinical studies using an AML model, a combination of a DNA methylation inhibitor AZA and CD47 blockade via 5F9 mAb have resulted in increased macrophage-mediated phagocytosis in vitro compared to single treatments, inhibited AML growth, and prolonged survival in xenograft mice models [251].